AZD1613
Phase 1Small molecule
AstraZenecaAZD1613 is one of 32 small molecule programs targeting Autosomal Dominant Polycystic Kidney Disease. It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
41 competitors in Autosomal Dominant Polycystic Kidney Disease
#DrugCompanyPhaseTrials
1Samsca
OtsukaApproved
Afinitor
NovartisApproved
Jardiance
Boehringer IngelheimApproved
Lesinurad
EEsperion Therapeutics, Inc.
Approved
Lanreotide Acetate
AAlbireo, an Ipsen Company
Approved
Sandostatin
Sun PharmaApproved
Versed
CConrado Roberto Hoffmann Filho
Approved
Aldactone
PfizerPhase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Reata
BiogenPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Autosomal Dominant Polycystic Kidney Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AZD1613. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company